Abstract
In Brazil, during the pandemic caused by COVID-19, screening for breast and cervical cancers was postponed or interrupted due to the prevailing health conditions. These neoplasms, however, are responsible for high morbidity and mortality among women in Brazil and have a major impact on the quality of life of this population and on public health. Thus, this study aims to evaluate the epidemiological behavior of hospitalization for cervical and breast cancer in Brazilian women, as well as the trend of screening tests and diagnosis of breast and cervical cancer in the years 2010 to 2022 in Brazil. This is an ecological research of time series, based on secondary data obtained from information systems of the country, about hospital admissions for breast and cervical cancer and screening methods used for these tumors. The data were analyzed in the Joinpoint Regression Program, to obtain the linear regression and temporal analysis of the variables. As results, there is a decrease in hospitalization rates for cervical cancer between the years 2010 and 2015 and a subsequent increase in 2019. Regarding breast cancer, there was an increase in hospitalizations, until reaching a peak in 2019. For both, in the pandemic years, between 2020 and 2022, there is a decrease in Brazil and in all its regions. As for the tracking of these diseases, it was observed that the performance of mammograms and preventive tests showed a similar behavior, in which there is a higher supply of these tests until 2019 and a drop during the pandemic period. This leads to the conclusion that even though Brazil has several policies for screening and early diagnosis of these diseases, there is still instability in the offer of tests and that there was a precariousness in this area during the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GNC, TNBM, KTSC are funded by the Coordination for the Improvement of Higher Education Personnel- Brazil (CAPES): Financial Code 001. Funders will have no role in the study design, data collection and analysis, publication decision or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The information obtained for the elaboration of the research came from secondary sources and were collected by public domain databases and, therefore, did not need to be submitted to the Research Ethics Committee appreciation, as recommended by the Brazilian Resolution No. 510, of April 07, 2016.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript.
